Literature DB >> 23045159

Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts.

Thomas Hügle1, Steven O'Reilly, Rachel Simpson, Marina D Kraaij, Venetia Bigley, Matthew Collin, Anja Krippner-Heidenreich, Jacob M van Laar.   

Abstract

OBJECTIVE: The role of tumor necrosis factor (TNF) in systemic sclerosis (SSc) remains controversial. The present study was undertaken to investigate the influence of TNF receptor (TNFR)-costimulated lymphocytes on collagen expression in fibroblasts.
METHODS: TNFR expression on mononuclear cells from the dermis and blood of SSc patients was assessed by flow cytometry. Peripheral blood CD3+ lymphocytes were activated with CD3/CD28 beads and costimulated with TNFR-selective variants. Expression of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), IL-10, and IL-13 was detected by enzyme-linked immunosorbent assay or quantitative reverse transcription-polymerase chain reaction. Healthy fibroblasts were incubated with conditioned media from TNFR-costimulated T lymphocytes, and type I collagen expression was quantified.
RESULTS: TNFRI and TNFRII were up-regulated on dermal T lymphocytes from patients with diffuse cutaneous SSc. TNFRII expression correlated with skin thickening. After CD3/CD28 activation, peripheral blood lymphocytes from SSc patients produced more IL-6, sIL-6R, and IL-13 compared to healthy lymphocytes. Costimulation with TNFRI-selective ligands and soluble TNF further increased IL-6 expression, whereas costimulation with TNFRII led to greater release of sIL-6R. IL-10 expression, which normally occurs after TNFRII costimulation, was impaired in SSc T cells. Supernatants of TNF-costimulated SSc lymphocytes induced higher type I collagen expression in fibroblasts, which was partially reversible by dual inhibition of IL-6 and IL-13. Expression of TNFR and IL-6 in the dermis was reversible in a patient who received lymphoablative therapy prior to autologous hematopoietic stem cell transplantation.
CONCLUSION: TNF-costimulated T lymphocytes from SSc patients have a propensity to secrete profibrotic cytokines, while the ability to produce IL-10 is weakened. These results suggest that T lymphocytes in SSc support fibrosis, but might lack the capacity to resolve inflammation.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23045159      PMCID: PMC6588536          DOI: 10.1002/art.37738

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  48 in total

1.  Ultrastructure of cutaneous cellular infiltrates in scleroderma.

Authors:  R Fleischmajer; J S Perlish; W P West
Journal:  Arch Dermatol       Date:  1977-12

Review 2.  STAT3: a central mediator of pulmonary fibrosis?

Authors:  Cecilia M Prêle; Eric Yao; Robert J J O'Donoghue; Steven E Mutsaers; Darryl A Knight
Journal:  Proc Am Thorac Soc       Date:  2012-07

3.  Early T cell activation in the skin from patients with systemic sclerosis.

Authors:  A Kalogerou; E Gelou; S Mountantonakis; L Settas; E Zafiriou; L Sakkas
Journal:  Ann Rheum Dis       Date:  2005-08       Impact factor: 19.103

4.  Mast cells are a source of transforming growth factor β in systemic sclerosis.

Authors:  Thomas Hügle; Vanessa Hogan; Kathryn E White; Jacob M van Laar
Journal:  Arthritis Rheum       Date:  2011-03

5.  Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses.

Authors:  P Scheurich; B Thoma; U Ucer; K Pfizenmaier
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

6.  Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis.

Authors:  C Mavalia; C Scaletti; P Romagnani; A M Carossino; A Pignone; L Emmi; C Pupilli; G Pizzolo; E Maggi; S Romagnani
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

7.  Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice.

Authors:  L A Ortiz; J Lasky; R F Hamilton; A Holian; G W Hoyle; W Banks; J J Peschon; A R Brody; G Lungarella; M Friedman
Journal:  Exp Lung Res       Date:  1998 Nov-Dec       Impact factor: 2.459

8.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor.

Authors:  M Grell; E Douni; H Wajant; M Löhden; M Clauss; B Maxeiner; S Georgopoulos; W Lesslauer; G Kollias; K Pfizenmaier; P Scheurich
Journal:  Cell       Date:  1995-12-01       Impact factor: 41.582

9.  Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha.

Authors:  Carlo Chizzolini; Yann Parel; Carmelina De Luca; Alan Tyndall; Anita Akesson; Agneta Scheja; Jean-Michel Dayer
Journal:  Arthritis Rheum       Date:  2003-09

10.  Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression.

Authors:  Timothy R D J Radstake; Lenny van Bon; Jasper Broen; Mark Wenink; Kim Santegoets; Yanhui Deng; Anila Hussaini; Robert Simms; William W Cruikshank; Robert Lafyatis
Journal:  PLoS One       Date:  2009-06-22       Impact factor: 3.240

View more
  21 in total

Review 1.  Role of innate immune system in systemic sclerosis.

Authors:  Nicola Fullard; Steven O'Reilly
Journal:  Semin Immunopathol       Date:  2015-07-10       Impact factor: 9.623

Review 2.  The role of the acquired immune response in systemic sclerosis.

Authors:  Carlo Chizzolini; Francesco Boin
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

Review 3.  Genetics of systemic sclerosis.

Authors:  Lara Bossini-Castillo; Elena López-Isac; Maureen D Mayes; Javier Martín
Journal:  Semin Immunopathol       Date:  2015-06-02       Impact factor: 9.623

Review 4.  Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and how can we expect the field to evolve?

Authors:  Matlock A Jeffries; Amr H Sawalha
Journal:  Expert Rev Clin Immunol       Date:  2015-01       Impact factor: 4.473

5.  Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein.

Authors:  Steven O'Reilly; Marzena Ciechomska; Rachel Cant; Jacob M van Laar
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

Review 6.  Emerging role of epigenetics in systemic sclerosis pathogenesis.

Authors:  M Ciechomska; J M van Laar; S O'Reilly
Journal:  Genes Immun       Date:  2014-07-17       Impact factor: 2.676

7.  Serum amyloid A induces interleukin-6 in dermal fibroblasts via Toll-like receptor 2, interleukin-1 receptor-associated kinase 4 and nuclear factor-κB.

Authors:  Steven O'Reilly; Rachel Cant; Marzena Ciechomska; James Finnigan; Fiona Oakley; Sophie Hambleton; Jacob M van Laar
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

8.  Chronic exposure of interleukin-13 suppress the induction of matrix metalloproteinase-1 by tumour necrosis factor α in normal and scleroderma dermal fibroblasts through protein kinase B/Akt.

Authors:  M L Brown Lobbins; B R Shivakumar; A E Postlethwaite; K A Hasty
Journal:  Clin Exp Immunol       Date:  2017-10-02       Impact factor: 4.330

Review 9.  Interleukin-6: a new therapeutic target in systemic sclerosis?

Authors:  Steven O'Reilly; Rachel Cant; Marzena Ciechomska; Jacob M van Laar
Journal:  Clin Transl Immunology       Date:  2013-04-12

10.  IL-13 mediates collagen deposition via STAT6 and microRNA-135b: a role for epigenetics.

Authors:  Steven O'Reilly; Marzena Ciechomska; Nicola Fullard; Stefan Przyborski; Jacob M van Laar
Journal:  Sci Rep       Date:  2016-04-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.